Karo Pharma acquires a 10 product portfolio from Leo Pharma
March 1, 2018
Leo Pharma has divested a 10 product portfolio to Swedish-based Karo Pharma. It is fully aligned with Leo Pharma 2025 strategy to focus on new medical solutions and divest current. The deal value amounted to EUR 260 m.
ⓘ This story was originally featured in our daily M&A Insights newsletter.